A real-world study of diverse RC48-based regimens across disease stages of urothelial carcinoma
Bladder · 2025
DOI: 10.14440/bladder.0169 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bladder, 2025. Verfasst von Liangliang Qing und 8 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
RC48, a human epidermal growth factor receptor 2 (HER2)-targeting antibody–drug conjugate (ADC), has been approved in China for the treatment of HER2-positive metastatic urothelial carcinoma.
Objective
This study evaluated the efficacy and safety of various RC48-based regimens in patients with urothelial carcinoma across disease stages in real-world settings.
Methods
We retrospectively analyzed data from 56 patients at different disease stages who were treated at the Second Hospital of Lanzhou University between March 2023 and June 2024. RC48-ADC was administered as a monotherapy or in combination with immunotherapy until discontinuation due to disease progression, intolerable toxicity, death, or other reasons.
Results
Outcomes included the objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and treatment-related adverse events (TRAEs). The median patient age was 67.5 years, with 83.9% being male. Of all patients, 14 (25.0%) received RC48-ADC monotherapy, and 42 (75.0%) received RC48-ADC combined with immunotherapy. Response rates were as follows: 15 patients (26.8%) achieved complete remission, 21 (37.5%) attained partial remission, 14 (25.0%) had stable disease, and 6 (10.7%) suffered from disease progression. The overall ORR was 64.3%, with rates of 70.0% and 60.0% in first-line and second-line treatment groups, respectively. The median PFS lasted for 6 months (range: 5–7 months), whereas the median OS was not reached. The most common TRAEs were peripheral sensory neuropathy (58.9%), fatigue (48.2%), decreased appetite (42.9%), and weight loss (37.5%).
Conclusion
No increased incidence of TRAEs was observed in patients with poor performance status or impaired kidney function. RC48-ADC demonstrated efficacy and safety in patients with urothelial carcinoma, providing clinical benefits regardless of performance status or renal function.
Zitieren
APA
Qing, L., Li, L., Li, Q., Yang, Y., Xu, W., Wang, Y., Li, R., You, C., & Dong, Z. (2025). A real-world study of diverse RC48-based regimens across disease stages of urothelial carcinoma. Bladder. https://doi.org/10.14440/bladder.0169
Vancouver
Qing L, Li L, Li Q, Yang Y, Xu W, Wang Y, et al. A real-world study of diverse RC48-based regimens across disease stages of urothelial carcinoma. Bladder. 2025. doi:10.14440/bladder.0169
BibTeX
@article{Qing2025,
author = {Qing, Liangliang and Li, Lingyi and Li, Qingchao and Yang, Yongjin and Xu, Wenbo and Wang, Yanan and Li, Rongxing and You, Chengyu and Dong, Zhilong},
title = {A real-world study of diverse RC48-based regimens across disease stages of urothelial carcinoma},
journal = {Bladder},
year = {2025},
doi = {10.14440/bladder.0169}
}
EUVIMED